Updated Findings With Ruxolitinib in Polycythemia Vera
Jean-Jacques Kiladjian, MD, PhD, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera still remained on treatment with ruxolitinib.
Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology at Paris Diderot University, discusses the 5-year follow-up results from the RESPONSE trial, where more than 65% of patients with polycythemia vera (PV) still remained on treatment with ruxolitinib (Jakafi).
In addition, more than 74% of patients who achieved a primary response maintained this response, Kiladjian says. Of the patients who achieved a complete hematologic response, 54% maintained that response as well.
Kiladjian says he was pleased to see that molecular response was achieved in these patients as the meanJAK2
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
